

TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED
(Formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited)
(Incorporated in the People's Republic of China)
(Company Registration No.: 91120000103100784F)

RESOLUTIONS PASSED AT THE 4TH BOARD MEETING FOR FY2026

The board of directors (the “Board”) and every individual director of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited) (the “Company”) hereby confirm that they will individually and collectively accept full responsibility for the accuracy of the information given in this announcement, and confirm, having made all reasonable enquiries, that to the best of their knowledge and belief, the facts stated in this announcement are fair and accurate in all material respects as at the date of this announcement, and that there are no material facts the omission of which would make any statement in this announcement misleading.

On 28 April 2026, the Company duly convened its 4th Board meeting for the financial year ending 31 December 2026 (“FY2026”) via a combination of a physical meeting and teleconference. The meeting was held in compliance with the applicable Company Law and Securities Law, as well as the Articles of Association of the Company. The following resolutions were duly passed at the meeting:

1. That the full text and summary of the Company’s first quarter financial statements for FY2026, prepared in accordance with the accounting standards of the People’s Republic of China and the International Financial Reporting Standards, be approved.

To the best of the knowledge of the Directors and management of the Company, there is no other information that would render the contents of the aforesaid financial statements false or misleading.

2. That the Evaluation Report on the Company’s 2025 Action Plan for “Quality Improvement, Efficiency Enhancement, and Focus on Shareholder Returns” (2025 年度 “提质增效重回报” 行动方案) and the Adoption of the Company’s 2026 Action Plan for “Quality Improvement, Efficiency Enhancement, and Focus on Shareholder Returns” (2026 年度 “提质增效重回报” 行动方案) be approved.
3. That the proposed termination of the equity custody agreement (股权托管协议) (the “**Equity Custody Agreement**”) entered into among the Company, Tianjin Medicine Asset Management Co., Ltd. (天津医药资产管理有限公司) (“**TM Asset Management Co.**”) and Tianjin Pharmaceutical Group Jin Yi Tang Chain Co., Ltd. (天津医药集团津一堂连锁股份有限公司) (the “**Target Company**”) in relation to the custody of the 100% equity interest in the Target Company, which constitutes an interested person transaction, be approved.

On 20 June 2025, the Company convened its 4th Board meeting for the financial year ended 31 December 2025, at which the Board considered and approved, amongst others, the Company’s entry into the Equity Custody Agreement with TM Asset Management Co. and the Target Company in relation to the custody of the 100% equity interest in the Target Company for a custody period of three (3) years, which constitutes an interested person transaction.¹ Pursuant to the terms of the

¹ For further details of the Equity Custody Agreement, please refer to the [Company’s announcement dated 20 June 2025](#).

Equity Custody Agreement and as mutually agreed by the parties thereto, the parties have agreed to the early termination of the Equity Custody Agreement.

Mr. Guo Min, Ms. Wang Lei, Mr. Xing Jianhua, and Ms. Mao Weiwen, being interested Directors, abstained from voting on this resolution.

By Order of the Board

Jiao Yan
Secretary to the Board of Directors
29 April 2026